Skip to main content
SpringerLink
Log in

Antifolate Drugs in Cancer Therapy

  • Book
  • © 1999

Overview

Editors:
  1. Ann L. Jackman

    1. The Cancer Research Campaign Centre for Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey, UK

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

Part of the book series: Cancer Drug Discovery and Development (CDD&D)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (22 chapters)

  1. Front Matter

    Pages i-x
    Download chapter PDF

  2. Antifolate Drugs

    • Robert C. Jackson
    Pages 1-12

  3. Folate Biochemistry in Relation to Antifolate Selectivity

    • Roy L. Kisliuk
    Pages 13-36

  4. Clinical Pharmacology and Resistance to Dihydrofolate Reductase Inhibitors

    • Richard Gorlick, Joseph R. Bertino
    Pages 37-57

  5. Development of Nonpolyglutamatable DHFR Inhibitors

    • Andre Rosowsky
    Pages 59-100

  6. Fluoropyrimidines as Antifolate Drugs

    • G. J. Peters, C. H. Köhne
    Pages 101-145

  7. Raltitrexed (TomudexTM), a Highly Polyglutamatable Antifolate Thymidylate Synthase Inhibitor

    • Leslie R. Hughes, Trevor C. Stephens, F. Thomas Boyle, Ann L. Jackman
    Pages 147-165

  8. Tomudex

    • Philip Beale, Stephen Clarke
    Pages 167-181

  9. Preclinical Pharmacology Studies and the Clinical Development of a Novel Multitargeted Antifolate, MTA (LY231514)

    • Chuan Shih, Donald E. Thornton
    Pages 183-201

  10. GW1843

    • Gary K. Smith, Joseph W. Bigley, Inderjit K. Dev, David S. Duch, Robert Ferone, William Pendergast
    Pages 203-227

  11. Preclinical and Clinical Studies with the Novel Thymidylate Synthase Inhibitor Nolatrexed Dihydrochloride (ThymitaqTM, AG337)

    • Andy Hughes, A. Hilary Calvert
    Pages 229-241

  12. ZD9331

    • F. Thomas Boyle, Trevor C. Stephens, S. D. Averbuch, Ann L. Jackman
    Pages 243-260

  13. Preclinical and Clinical Evaluation of the Glycinamide Ribonucleotide Formyltransferase Inhibitors Lometrexol and LY309887

    • Laurane G. Mendelsohn, John F. Worzalla, Jackie M. Walling
    Pages 261-280

  14. AG2034

    • Theodore J. Boritzki, Cathy Zhang, Charlotte A. Bartlett, Robert C. Jackson
    Pages 281-292

  15. Receptor- and Carrier-Mediated Transport Systems for Folates and Antifolates

    • G. Jansen
    Pages 293-321

  16. Folates as Chemotherapeutic Modulators

    • Julio Barredo, Marlene A. Bunni, Raghunathan Kamasamudram, David G. Priest
    Pages 323-337

  17. Antifolate Polyglutamylation in Preclinical and Clinical Antifolate Resistance

    • John J. McGuire
    Pages 339-363

  18. Antifolates in Combination Therapy

    • Stephen P. Ackland, Rosemary Kimbell
    Pages 365-382

  19. Pharmacodynamic Measurements and Predictors of Response to Thymidylate Synthase Inhibitors

    • David Farrugia, Patrick G. Johnston
    Pages 383-396

  20. Molecular Regulation of Expression of Thymidylate Synthase

    • Edward Chu, Jingfang Ju, John C. Schmitz
    Pages 397-408
Back to top

Keywords

About this book

In Antifolate Drugs in Cancer Therapy, Ann Jackman and a panel of highly regarded researchers comprehensively review the current status of novel antifolates, an important class of anticancer drugs. The distinguished contributors discuss the preclinical and clinical pharmacology of methotrexate, other dihydrofolate reductase inhibitors,
5-fluorouracil, and the new generation of antifolates-the thymidylate synthase and glycinamide ribonucleotide formyltransferase inhibitors. In addition, they review in depth the modulation of antifolate drugs, folate and antifolate transport mechanisms, polyglutamation, resistance, and drug combinations, as well as pharmacogenomics, pharmacodynamics, regulation of gene expression, and mechanisms of cell death.

The wide and progressive scope of Antifolate Drugs in Cancer Therapy provides entré to exciting new avenues for future research, and constitutes a new standard reference for all basic scientists and clinicians engaged in cancer therapeutics.

Editors and Affiliations

  • The Cancer Research Campaign Centre for Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey, UK

    Ann L. Jackman

Bibliographic Information

  • Book Title: Antifolate Drugs in Cancer Therapy

  • Editors: Ann L. Jackman

  • Series Title: Cancer Drug Discovery and Development

  • DOI: https://doi.org/10.1007/978-1-59259-725-3

  • Publisher: Humana Totowa, NJ

  • eBook Packages: Springer Book Archive

  • Copyright Information: Springer Science+Business Media New York 1999

  • Hardcover ISBN: 978-0-89603-596-6Published: 22 January 1999

  • Softcover ISBN: 978-1-4757-4521-4Published: 24 March 2013

  • eBook ISBN: 978-1-59259-725-3Published: 22 January 1999

  • Series ISSN: 2196-9906

  • Series E-ISSN: 2196-9914

  • Edition Number: 1

  • Number of Pages: X, 456

  • Number of Illustrations: 13 b/w illustrations

  • Topics: Pharmacy

Publish with us

Policies and ethics

Back to top

Search

Navigation